News

The latest on managing care, value-based care, insurance markets, payers & providers

Single-source drugs get formulary preference

Managed care organizations often place costly new drugs on a formulary's priciest tier, but products for which substitutes do not exist often are made available at lower copayment levels. Average copayments for single-source, brand-name products are considerably lower than those for branded compounds available from multiple sources. Interpretation suggests that employers and MCOs recognize that access to products for which substitutes are unavailable — particularly when they can save lives or reduce morbidity — is important, even though the relative cost of most single-source products is high.

Average copayments, by product source, 1999

SOURCE: WYETH-AYERST PRESCRIPTION DRUG BENEFIT COST AND PLAN DESIGN SURVEY, COPYRIGHT 2000, PHARMACY BENEFIT MANAGEMENT INSTITUTE, TEMPE, ARIZ.

Subscribe to Our Newsletters

Monthly table of contents

Be notified as each issue of Managed Care is available online.

Biweekly newsletter

Recent topics have included:

  • Doug Jones and the ACA, Epic misses a White House meeting, and man caves for man-flu sufferers
  • CVS-Aetna deal may trigger merger mania, Johns Hopkins criticized for lack of asthma prevention, & Columbia sees free-ride future for all of its med students

PTCommunity news

New drug approvals, clinical trials, drug management. Three times per week.